Co-Authors
This is a "connection" page, showing publications co-authored by KARL-DIMITER BISSIG and WILLIAM LAGOR.
Connection Strength
1.638
-
In vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential gene. Sci Transl Med. 2025 Feb 12; 17(785):eadk3920.
Score: 0.247
-
In vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential gene. bioRxiv. 2023 Jul 29.
Score: 0.222
-
Rescue of glutaric aciduria type I in mice by liver-directed therapies. Sci Transl Med. 2023 04 19; 15(692):eadf4086.
Score: 0.218
-
Targeting the Apoa1 locus for liver-directed gene therapy. Mol Ther Methods Clin Dev. 2021 Jun 11; 21:656-669.
Score: 0.190
-
A human liver chimeric mouse model for non-alcoholic fatty liver disease. JHEP Rep. 2021 Jun; 3(3):100281.
Score: 0.189
-
Rapid Disruption of Genes Specifically in Livers of Mice Using Multiplex CRISPR/Cas9 Editing. Gastroenterology. 2018 12; 155(6):1967-1970.e6.
Score: 0.158
-
CRISPR/Cas9: at the cutting edge of hepatology. Gut. 2017 07; 66(7):1329-1340.
Score: 0.144
-
Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. Sci Rep. 2017 03 16; 7:44624.
Score: 0.143
-
Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nat Commun. 2015 Jun 17; 6:7339.
Score: 0.127